'Amgen To Launch US Eylea Biosimilar After Ruling In Regeneron Patent Case' - Reuters News
Portfolio Pulse from Benzinga Newsdesk
Amgen is set to launch a biosimilar version of Regeneron's Eylea after a favorable U.S. court ruling. The decision allows Amgen to proceed despite Regeneron's appeal, impacting Regeneron's $5.89 billion U.S. sales from Eylea.
October 22, 2024 | 7:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron faces potential revenue loss as Amgen launches a biosimilar to its Eylea drug following a court ruling against Regeneron's appeal.
The launch of Amgen's biosimilar could reduce Regeneron's market share and revenue from Eylea, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Amgen will launch a biosimilar version of Eylea after a favorable court ruling, potentially increasing its market share in the eye care sector.
The court ruling allows Amgen to launch its biosimilar, which could lead to increased revenues and market share in the eye care sector, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90